Bracco to establish operations in U.K., Ireland

Article

Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck

Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck Pharmaceuticals Imaging, a division of Merck of Germany. Merck Pharmaceuticals will continue to distribute Bracco’s contrast media products in the U.K. and Ireland until Bracco’s operations are in place. Bracco products distributed by Merck include x-ray contrast agents Niopam and Iomeron, as well as MRI agents ProHance and MultiHance.

The agreement is part of Bracco’s move to acquire Merck’s 50% share in its imaging and pharmaceutical businesses, which was announced in January. Pending regulatory approval, Bracco will pay Merck $900 million over five years (SCAN 1/12/00).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.